^
    Back
    Association details:
    Biomarker:HER-2 amplification
    Cancer:Non Small Cell Lung Cancer
    Drug:Vizimpro (dacomitinib) (pan-HER inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO

    Excerpt:
    ...HER-2 mutation or HER-2 amplification....
    Trial ID:
    ARCHER 1042
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

    Excerpt:
    ...Cohort B (select sites only): patients with HER2 amplified or HER2 mutation-positive NSCLC; may have had prior therapy...
    Trial ID:
    NCT00818441
    Less C2 evidence
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Ann Oncol
    Title:

    Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors

    Excerpt:
    We enrolled 30 patients with HER2-mutant (n = 26, all in exon 20 including 25 insertions and 1 missense mutation) or HER2-amplified lung cancers (n = 4)...No partial responses occurred in four patients with tumors with HER2 amplification.
    DOI:
    10.1093/annonc/mdv186
    Trial ID:
    NCT00818441